ABSTRACT
This study examines a description of pituitary tumors considering an anatomopathological casuistic. The study of the tumors of the Central Nervous System (CNS) include the pituitary gland, located in the sella turcica. The pathology of the sellar region is represented by the adenomas, tumors of slow development with or without endocrine secretion, that usually involve the population of young adults. The aim of this report, was to describe the casuistic of the " J. Fernandez Hospital" between the years 2000 through 2017. A retrospective review was performed and 234 samples of the sellar region were processed. Mean age was 42 years with a range of 17 to 77 years. Sex distribution was 57% women and 43 % men. Of these, 77% of the cases resulted adenomas. The conclusions obtained in the study are detailed.
Subject(s)
Humans , Adult , Middle Aged , Aged , Pituitary Gland, Anterior/pathology , Pituitary Neoplasms/pathology , Sella Turcica/pathology , Central Nervous System/pathology , Multiple Endocrine Neoplasia Type 1/genetics , DiagnosisABSTRACT
Prostate cancer is the most prevalent type of cancer in men around the world. Due to its high incidence, new therapies have been evaluated, including drugs capable of inhibiting the FGF/VEGF pathways, as Nintedanib. The aim herein was to evaluate the Nintedanib therapeutic effects on morphology and COX-2 and IL-17 levels in the prostate anterior lobe in different grades of the tumor progression in TRAMP mice. Animals were treated with Nintedanib at a dose of 10â¯mg/kg/day in initial and intermediate grades of tumor development. At the end of treatment, the prostate anterior lobe was collected and submitted to morphological, immunohistochemical and Western Blotting analyses. The results showed that Nintedanib delayed the prostate carcinogenesis progression, with over 20% of reduction in frequency of tissue injuries, particularly in the group treated from 12 to 16 weeks of age. Also, decreased COX-2 and IL-17 levels were observed in both groups treated with Nintedanib in the prostate anterior lobe. Thus, we concluded that Nintedanib was effective in delaying tumor progression and, despite not directly acting on inflammation, Nintedanib may adversely affect inflammatory pathways, favoring prostate cancer delay.
Subject(s)
Cyclooxygenase 2/genetics , Indoles/administration & dosage , Inflammation/drug therapy , Interleukin-17/genetics , Prostatic Neoplasms/drug therapy , Animals , Carcinogenesis/drug effects , Disease Progression , Gene Expression Regulation, Neoplastic/drug effects , Humans , Indoles/adverse effects , Inflammation/chemically induced , Inflammation/genetics , Inflammation/pathology , Male , Mice , Pituitary Gland, Anterior/drug effects , Pituitary Gland, Anterior/pathology , Prostate/drug effects , Prostate/pathology , Prostatic Neoplasms/genetics , Prostatic Neoplasms/pathology , Receptors, Tumor Necrosis Factor, Member 25/geneticsABSTRACT
IL-6 is a pleiotropic cytokine with multiple pathophysiological functions. As a key factor of the senescence secretome, it can not only promote tumorigenesis and cell proliferation but also exert tumor suppressive functions, depending on the cellular context. IL-6, as do other cytokines, plays important roles in the function, growth and neuroendocrine responses of the anterior pituitary gland. The multiple actions of IL-6 on normal and adenomatous pituitary function, cell proliferation, angiogenesis and extracellular matrix remodeling indicate its importance in the regulation of the anterior pituitary. Pituitary tumors are mostly benign adenomas with low mitotic index and rarely became malignant. Premature senescence occurs in slow-growing benign tumors, like pituitary adenomas. The dual role of IL-6 in senescence and tumorigenesis is well represented in pituitary tumor development, as it has been demonstrated that effects of paracrine IL-6 may allow initial pituitary cell growth, whereas autocrine IL-6 in the same tumor triggers senescence and restrains aggressive growth and malignant transformation. IL-6 is instrumental in promotion and maintenance of the senescence program in pituitary adenomas.
Subject(s)
Adenoma/genetics , Cellular Senescence/genetics , Interleukin-6/genetics , Neovascularization, Pathologic/genetics , Pituitary Gland, Anterior/metabolism , Pituitary Neoplasms/genetics , Adenoma/metabolism , Adenoma/pathology , Animals , Autocrine Communication/genetics , Cell Cycle/genetics , Cell Proliferation , Extracellular Matrix/metabolism , Extracellular Matrix/pathology , Gene Expression Regulation , Humans , Interleukin-6/metabolism , Mitogen-Activated Protein Kinase Kinases/genetics , Mitogen-Activated Protein Kinase Kinases/metabolism , Neovascularization, Pathologic/metabolism , Neovascularization, Pathologic/pathology , Paracrine Communication/genetics , Phosphatidylinositol 3-Kinases/genetics , Phosphatidylinositol 3-Kinases/metabolism , Pituitary Gland, Anterior/pathology , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/pathology , STAT Transcription Factors/genetics , STAT Transcription Factors/metabolismABSTRACT
Humanin (HN) is a 24-amino acid peptide with cytoprotective action in several cell types such as neurons and testicular germ cells. Rattin (HNr), a homologous peptide of HN expressed in several adult rat tissues, also has antiapoptotic action. In the present work, we demonstrated by immunocytochemical analysis and flow cytometry the expression of HNr in the anterior pituitary of female and male adult rats as well as in pituitary tumor GH3 cells. HNr was localized in lactotropes and somatotropes. The expression of HNr was lower in females than in males, and was inhibited by estrogens in pituitary cells from both ovariectomized female and orquidectomized male rats. However, the expression of HNr in pituitary tumor cells was not regulated by estrogens. We also evaluated HN action on the proapoptotic effect of TNF-α in anterior pituitary cells assessed by the TUNEL method. HN (0.5 µM) per se did not modify basal apoptosis of anterior pituitary cells but completely blocked the proapoptotic effect of TNF-α in total anterior pituitary cells, lactotropes and somatotropes from both female and male rats [corrected]. Also, HN inhibited the apoptotic effect of TNF-α on pituitary tumor cells. In summary, our results demonstrate that HNr is present in the anterior pituitary gland, its expression showing sexual dimorphism, which suggests that gonadal steroids may be involved in the regulation of HNr expression in this gland. Antiapoptotic action of HN in anterior pituitary cells suggests that this peptide could be involved in the homeostasis of this gland. HNr is present and functional in GH3 cells, but it lacks regulation by estrogens, suggesting that HN could participate in the pathogenesis of pituitary tumors.
Subject(s)
Apoptosis/drug effects , Cytoprotection/drug effects , Intracellular Signaling Peptides and Proteins/metabolism , Pituitary Gland/metabolism , Pituitary Neoplasms/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Animals , Cell Line, Tumor , Estradiol/pharmacology , Estrogens/pharmacology , Female , Male , Orchiectomy , Ovariectomy , Pituitary Gland/drug effects , Pituitary Gland/pathology , Pituitary Gland, Anterior/drug effects , Pituitary Gland, Anterior/metabolism , Pituitary Gland, Anterior/pathology , Pituitary Neoplasms/pathology , Proteins/metabolism , Rats, WistarABSTRACT
Since anterior pituitary expresses prolactin receptors, prolactin secreted by lactotropes could exert autocrine or paracrine actions on anterior pituitary cells. In fact, it has been observed that prolactin inhibits its own expression by lactotropes. Our hypothesis is that prolactin participates in the control of anterior pituitary cell turnover. In the present study, we explored the action of prolactin on proliferation and apoptosis of anterior pituitary cells and its effect on the expression of the prolactin receptor. To determine the activity of endogenous prolactin, we evaluated the effect of the competitive prolactin receptor antagonist Δ1-9-G129R-hPRL in vivo, using transgenic mice that constitutively and systemically express this antagonist. The weight of the pituitary gland and the anterior pituitary proliferation index, determined by BrdU incorporation, were higher in transgenic mice expressing the antagonist than in wild-type littermates. In addition, blockade of prolactin receptor in vitro by Δ1-9-G129R-hPRL increased proliferation and inhibited apoptosis of somatolactotrope GH3 cells and of primary cultures of male rat anterior pituitary cells, including lactotropes. These results suggest that prolactin acts as an autocrine/paracrine antiproliferative and proapoptotic factor in the anterior pituitary gland. In addition, anterior pituitary expression of the long isoform of the prolactin receptor, measured by real-time PCR, increased about 10-fold in transgenic mice expressing the prolactin receptor antagonist, whereas only a modest increase in the S3 short-isoform expression was observed. These results suggest that endogenous prolactin may regulate its own biological actions in the anterior pituitary by inhibiting the expression of the long isoform of the prolactin receptor. In conclusion, our observations suggest that prolactin is involved in the maintenance of physiological cell renewal in the anterior pituitary. Alterations in this physiological role of prolactin could contribute to pituitary tumor development.
Subject(s)
Cell Proliferation/drug effects , Gene Expression Regulation , Hormone Antagonists/pharmacology , Pituitary Gland, Anterior/metabolism , Prolactin/analogs & derivatives , Prolactin/physiology , Receptors, Prolactin/metabolism , Animals , Apoptosis/drug effects , Cell Line , Cells, Cultured , Gene Expression Regulation/drug effects , Hormone Antagonists/metabolism , Male , Mice , Mice, Inbred BALB C , Mice, Transgenic , Organ Size , Pituitary Gland, Anterior/cytology , Pituitary Gland, Anterior/drug effects , Pituitary Gland, Anterior/pathology , Prolactin/antagonists & inhibitors , Prolactin/genetics , Prolactin/metabolism , Prolactin/pharmacology , Protein Isoforms/genetics , Protein Isoforms/metabolism , RNA, Messenger/metabolism , Rats , Rats, Wistar , Receptors, Prolactin/antagonists & inhibitors , Receptors, Prolactin/genetics , Recombinant Proteins/metabolism , Recombinant Proteins/pharmacology , Signal Transduction/drug effectsABSTRACT
Spindle cell oncocytoma of the adenohypophysis (SCO) is defined as spindle to epithelioid cells with oncocytic appearance presenting in the adenohypophysis. In contrast to pituitary adenomas, the SCO does not show immunoreactivity for neuroendocrine markers and pituitary hormones but co-expressed vimentin, S-100 protein, epithelial membrane antigen (EMA), and antimitochondrial antibody MU213-UC clone 131-1. We describe an SCO in an adult, a 42-year-old woman whose magnetic resonance (MR) images documented an intrasellar lesion located in the hypophysis. Histopathological examination showed a tumor composed predominantly of spindle cells. Immunohistochemical studies showed positivity for vimentin, S10, EMA, and antimitochondrial antibody MU213-UC clone 131. Cytokeratin (CK) (AE1/AE3), glial fibrillary acidic protein (GFAP), chromogranin, synaptophysin, PGP9.5, CD57, desmin, D2-40, smooth muscle actin (SMA), Bcl-2, progesterone receptor, and CD34 were negative. Neuropeptides were negative. With electron microscopy, the neoplastic cells appear filled with mitochondria, well-formed desmosomes, but lacked secretory granules. SPO is a rare non-endocrine neoplasm of the adenohypophysis with benign biological behavior corresponding to WHO grade I.
Subject(s)
Adenoma, Oxyphilic/pathology , Pituitary Gland, Anterior/pathology , Pituitary Neoplasms/pathology , Adult , Female , HumansABSTRACT
Cadmium (Cd) is widely used in industrial applications and is an important contaminant of agricultural products. As an endocrine disruptor, Cd modifies the hormone release of pituitary anterior lobe (PAL). This work was undertaken to evaluate a possible association between phospholipase D (PLD) and prolactin mRNA expressions and the activity of lactotrophs and folliculostellate cells (FSC) in PAL of Cd exposed adult male Wistar rats (Cd, 0.133 mM per liter for 2 months). The PALs were submitted to immunohistochemical and morphometric analysis to determine the percentage of lactotrophs (PRL-ir) and FSC (S-100-ir). Cultured PAL cells were stained with Hoechst 33258 to determine the presence of alterations in nuclear morphology consistent with apoptosis. The expressions of PLD and prolactin mRNA were assessed by RT-PCR. Cd treated rats showed a decrease of PLD mRNA levels that can be associated to both high number of apoptotic cells and increase of S-100 protein expression in FSC. Cd decreased prolactin mRNA expression, number of lactotrophs and percentage of PRL-ir suggesting a low availability of prolactin to be secreted from PAL. Cd modifies the lactotrophs activity of pituitary gland through biochemical, genomic and morphological changes and contributes directly or indirectly to the levels of serum prolactin.
Subject(s)
Cadmium Chloride/toxicity , Pituitary Gland, Anterior/drug effects , Animals , Apoptosis/drug effects , Cadmium Chloride/administration & dosage , Disease Models, Animal , Immunohistochemistry , Male , Phospholipase D/antagonists & inhibitors , Phospholipase D/metabolism , Pituitary Gland, Anterior/metabolism , Pituitary Gland, Anterior/pathology , Prolactin/antagonists & inhibitors , Prolactin/metabolism , RNA, Messenger/drug effects , RNA, Messenger/metabolism , Rats , Rats, Wistar , Structure-Activity RelationshipABSTRACT
Dopamine D2 receptor (D2R) knockout (KO) female mice develop chronic hyperprolactinemia and pituitary hyperplasia. Our objective was to study the expression of the mitogen fibroblast growth factor (FGF2) and its receptor, FGFR1, comparatively in pituitaries from KO and wild-type (WT) female mice. We also evaluated FGF2 subcellular localization and FGF2 effects on pituitary function. FGF2-induced prolactin release showed a similar response pattern in both genotypes, even though basal and FGF2-stimulated release was higher in KO. FGF2 stimulated pituitary cellular proliferation (MTS assay and [(3)H]thymidine incorporation), with no differences between genotypes. FGF2 concentration (measured by ELISA) in whole pituitaries or cultured cells was lower in KO (P < 0.00001 and 0.00014). Immunofluorescence histochemistry showed less FGF2 in pituitaries from KO females and revealed a distinct FGF2 localization pattern between genotypes, being predominantly nuclear in KO and cytosolic in WT pituitaries. Finally, FGF2 could not be detected in the conditioned media from pituitary cultures of both genotypes. FGFR1 levels (Western blot and immunohistochemistry) were higher in pituitaries of KO. Basal concentration of phosphorylated ERKs was lower in KO cells (P = 0.018). However, when stimulated with FGF2, a significantly higher increment of ERK phosphorylation was evidenced in KO cells (P < or = 0.02). We conclude that disruption of the D2R caused an overall decrease in pituitary FGF2 levels, with an increased distribution in the nucleus, and increased FGFR1 levels. These results are important in the search for reliable prognostic indicators for patients with pituitary dopamine-resistant prolactinomas, which will make tumor-specific therapy possible.
Subject(s)
Fibroblast Growth Factor 2/metabolism , Pituitary Gland, Anterior/metabolism , Pituitary Gland, Anterior/pathology , Prolactinoma/metabolism , Receptors, Dopamine D2/deficiency , Animals , Blotting, Western , Cell Growth Processes/physiology , Enzyme-Linked Immunosorbent Assay , Extracellular Signal-Regulated MAP Kinases/metabolism , Female , Hyperplasia , Immunohistochemistry , Mice , Mice, Inbred C57BL , Mice, Knockout , Microscopy, Confocal , Microscopy, Fluorescence , Phosphorylation , Pituitary Gland, Anterior/cytology , Prolactin/metabolism , Receptor, Fibroblast Growth Factor, Type 1/metabolism , Receptors, Dopamine D2/metabolismABSTRACT
Duchenne muscular dystrophy (DMD) is a recessive X-linked lethal condition which affects a boy in every 3300 births. It is caused by the absence of dystrophin, a protein occurring especially within the musculoskeletal system and in neurons in specific regions of the central nervous system (CNS). Growth hormone (GH) inhibition is believed to decrease the severity of DMD and could perhaps be used in its treatment. However, the underlying pathological mechanism is not known. The golden retriever muscular dystrophy dog (GRMD) represents an animal model in the study of DMD. In this paper we investigated the morphological aspects of the adenohypophysis as well as the total number and size of GH-granulated cells using design-based stereological methods in a limited number of dystrophic and healthy golden retrievers. GH-cells were larger (32.4%) in dystrophic dogs than in healthy animals (p=0.01) and they occupied a larger portion (62.5%) of the adenohypophysis volume (p=0.01) without changes in either adenohypophysis volume (p=0.893) or total number of GH-granulated cells (p=0.869). With regard to ultrastructure, granulated cells possessed double-layer electron-dense granules which were evenly distributed in the cytosol. Furthermore, these granules in dystrophic animals occupied a larger proportion of GH-granulated cell volume (66.9%; p=0.008) as well as of all GH-cells in the whole pars distalis of adenohypophysis (77.3%; p=0.035), albeit IGF-1 serum concentration was lower in severe cases. This suggests difficulties in the GH secretion that might possibly be associated to dystrophin absence. In contrast to earlier reports, our data suggest that a lower IGF-1 concentration may be more related to a severe, as opposed to a benign, clinical form of muscular dystrophy.
Subject(s)
Growth Hormone/metabolism , Insulin-Like Growth Factor I/metabolism , Muscular Dystrophy, Animal/metabolism , Pituitary Gland, Anterior/metabolism , Animals , Body Weight , Cell Count , Cell Size , Creatine Kinase/blood , Cytoplasmic Granules/ultrastructure , Disease Progression , Dogs , Dystrophin/genetics , Genotype , Insulin-Like Growth Factor I/analysis , Male , Muscular Dystrophy, Animal/genetics , Muscular Dystrophy, Animal/pathology , Pituitary Gland, Anterior/chemistry , Pituitary Gland, Anterior/pathology , Polymerase Chain Reaction , Reference ValuesABSTRACT
Hexavalent chromium (Cr VI) is a highly toxic metal and an environmental pollutant. Different studies indicate that Cr VI exposure adversely affects reproductive functions. This metal has been shown to affect several tissues and organs but Cr VI effects on pituitary gland have not been reported. Anterior pituitary hormones are central for the body homeostasis and have a fundamental role in reproductive physiology. The aim of this study was to evaluate the effect of Cr VI at the pituitary level both in vivo and in vitro. We showed that Cr VI accumulates in the pituitary and hypothalamus, and decreases serum prolactin levels in vivo but observed no effects on LH levels. In anterior pituitary cells in culture, the effect of Cr VI on hormone secretion followed the same differential pattern. Besides, lactotrophs were more sensitive to the toxicity of the metal. As a result of oxidative stress generation, Cr VI induced apoptosis evidenced by nuclear fragmentation and caspase 3 activation. Our results indicate that the anterior pituitary gland can be a target of Cr VI toxicity in vivo and in vitro, thus producing a negative impact on the hypothalamic-pituitary-gonadal axis and affecting the normal endocrine function.
Subject(s)
Apoptosis/drug effects , Environmental Pollutants/toxicity , Gonadotropins, Pituitary/metabolism , Pituitary Gland, Anterior/drug effects , Potassium Dichromate/toxicity , Acetylcysteine/pharmacology , Animals , Antioxidants/pharmacology , Caspase 3/metabolism , Cell Survival/drug effects , Cells, Cultured , Chromium/toxicity , Dose-Response Relationship, Drug , Environmental Pollutants/metabolism , Enzyme Activation/drug effects , Gonadotropins, Pituitary/blood , Hypothalamus/metabolism , Liver/metabolism , Luteinizing Hormone/metabolism , Male , Membrane Potential, Mitochondrial/drug effects , Pituitary Gland, Anterior/metabolism , Pituitary Gland, Anterior/pathology , Potassium Dichromate/metabolism , Prolactin/metabolism , Rats , Rats, Wistar , Reactive Oxygen Species/metabolism , Time FactorsABSTRACT
OBJECTIVE: PROP1 mutations are the most common cause of genetic combined pituitary hormone deficiency (CPHD). The aim of this study was to investigate the PROP1 gene in two siblings with CPHD. DESIGN: Pituitary function and imaging assessment and molecular analysis of PROP1. PATIENTS: Two siblings, born to consanguineous parents, presented with GH deficiency associated with other pituitary hormone deficiencies (TSH, PRL and gonadotrophins). The male sibling also had an evolving cortisol deficiency. METHODS: Pituitary size was evaluated by magnetic resonance imaging (MRI). PROP1 gene analysis was performed by polymerase chain reaction (PCR), automatic sequencing and Southern blotting. Amplification of sequence tag sites (STS) and the Q8N6H0 gene flanking PROP1 were performed to define the extension of PROP1 deletion. RESULTS: MRI revealed a hypoplastic anterior pituitary in the girl at 14 years and pituitary enlargement in the boy at 18 years. The PROP1 gene failed to amplify in both siblings, whereas other genes were amplified. Southern blotting analysis revealed the PROP1 band in the controls and confirmed complete PROP1 deletion in both siblings. The extension of the deletion was 18.4 kb. The region flanking PROP1 contains several Alu core sequences that might have facilitated stem-loop-mediated excision of PROP1. CONCLUSIONS: We report here a complete deletion of PROP1 in two siblings with CPHD phenotype.
Subject(s)
Dwarfism, Pituitary/genetics , Homeodomain Proteins/genetics , Hypopituitarism/genetics , Adolescent , Blotting, Southern , Consanguinity , Dwarfism, Pituitary/pathology , Female , Gene Deletion , Homozygote , Humans , Hypopituitarism/pathology , Male , Pituitary Gland, Anterior/pathology , SiblingsABSTRACT
Our previous work showed that tumor necrosis factor (TNF)-alpha and FasL induce apoptosis of anterior pituitary cells. To further analyze the effect of these proapoptotic factors, we infected primary cultures from rat anterior pituitary, GH3 and AtT20 cells with first-generation adenoviral vectors encoding TNF-alpha, FasL or, as a control, beta-galactosidase (beta-Gal), under the control of the human cytomegalovirus promoter. Successful expression of the encoded transgenes was determined by immunocytochemistry. Although we observed basal expression of TNF-alpha and FasL in control cultures of anterior pituitary cells, fluorescence-activated cell sorting (FACS) cell cycle analysis showed that the overexpression of TNF-alpha or FasL increases the percentage of hypodiploid lactotropes and somatotropes. Nuclear morphology and TUNEL staining revealed that the cells undergo an apoptotic death process. We detected strong immunoreactivity for TNFR1 and Fas in the somatolactotrope cell line GH3. TNF-alpha, but not FasL, was expressed in control cultures of GH3 cells. The infection of GH3 cells with adenovirus encoding TNF-alpha or FasL increased the percentages of hypodiploid and TUNEL-positive cells. TNF-alpha or FasL immunoreactivity was not observed in the corticotrope cell line AtT20. However, adenovirus encoding TNF-alpha or FasL efficiently transduced these cells and increased the percentages of hypodiploid and TUNEL-positive cells. The expression of beta-Gal was detected in all these cultures but did not affect cell viability. In conclusion, these results suggest that death signaling cascades triggered by TNF receptor 1 (TNFR1) and Fas are present in both normal and tumoral pituitary cells. Therefore, overexpression of proapoptotic factors could be a useful tool in the therapy of pituitary adenomas.
Subject(s)
Adenoviridae/genetics , Genetic Vectors/administration & dosage , Membrane Glycoproteins/genetics , Pituitary Gland, Anterior/cytology , Pituitary Neoplasms/pathology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factors/genetics , Animals , Apoptosis , Cell Line, Tumor , Fas Ligand Protein , Female , Flow Cytometry , Gene Expression , Genetic Vectors/genetics , Immunohistochemistry/methods , Membrane Glycoproteins/metabolism , Pituitary Gland, Anterior/metabolism , Pituitary Gland, Anterior/pathology , Pituitary Neoplasms/metabolism , Rats , Rats, Sprague-Dawley , Rats, Wistar , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factors/metabolismABSTRACT
Cadmium (Cd2+) is a potent toxic metal for both plants and animals. Chronic exposure to low doses of Cd2+ results in damage to several organs. We have previously reported that Cd2+ induces apoptosis in anterior pituitary cells by a caspase- and oxidative stress-dependent mechanism. Nitric oxide (NO) synthesis is affected by Cd2+ in several systems. NO has been shown to be either cytoprotective or cytotoxic in many systems. The aim of this study was to evaluate the possible participation of NO in the cytotoxic effect of Cd2+ on rat anterior pituitary cells. Cell viability was evaluated by mitochondrial dehydrogenase activity assay and confirmed by microscopy, studying nuclear morphology. Here we show that DETA NONOate ((Z)-1-[2 (2-aminoethyl)-N-(2-ammonioethyl)amino]diazen-1-ium-1,2-diolate), a long-term NO donor, at concentrations below 0.5 mM, reduces nuclear condensation and fragmentation and reverses the decrease in cellular activity induced by Cd2+. Cd2+, by itself, induced NO synthesis, and inhibition of this synthesis enhanced Cd2+ cytotoxicity. NO also prevented caspase-3 activation and lipidic peroxidation induced by Cd2+. The NO/cGMP pathway does not seem to be involved in the cytoprotective effect of NO. These results indicate that NO has a cytoprotective role in Cd2+ -induced apoptosis, suggesting that endogenous NO could have a physiological role in protecting anterior pituitary cells.
Subject(s)
Apoptosis/drug effects , Arginine/pharmacology , Cadmium/toxicity , Nitric Oxide/pharmacology , Pituitary Gland, Anterior/drug effects , Animals , Male , Nitric Oxide Donors/pharmacology , Nitroso Compounds/pharmacology , Pituitary Gland, Anterior/cytology , Pituitary Gland, Anterior/pathology , Rats , Rats, WistarABSTRACT
OBJECTIVE: Chronic stress is characterized by an increased activity of the hypothalamic-pituitary-adrenocortical axis and decreased humoral and cell-mediated immune responses. In the rat, corticosterone is the principal natural immune suppressor. Neurointermediate pituitary lobectomy (NIL) in rats induces diabetes insipidus and protracted increases in basal adrenocorticotropin and corticosterone plasma levels, a situation that resembles chronic stress. In this paper, we evaluated the effects of NIL on humoral (hemagglutinin titers and footpad swelling to sheep red blood cells--SRBC) and cell-mediated immune responses (contact hypersensitivity to dinitrochlorobenzene). METHODS: The studies were conducted on NIL Wistar rats (body weight 150-200 g) 3 weeks after surgery. For comparisons, nonoperated control rats were used. RESULTS: NIL resulted in an increased water intake. Body weight gain and adrenal, thymus, and spleen weights were within the range of nonoperated controls. Eight days after SRBC immunizations a second SRBC injection into the footpad resulted in a decreased swelling response in NIL rats. The hemagglutinin titers were also reduced in the NIL rats. CONCLUSIONS: These results indicate that: (1) NIL reduces humoral immune responses and decreases the cell-mediated immune response; (2) the immune alterations are most likely due to the increased activity of the hypothalamic-pituitary-adrenocortical axis induced by NIL, and (3) NIL animals constitute a valuable paradigm to study hypothalamic-pituitary-immune interactions.
Subject(s)
Antibody Formation/immunology , Immunity, Cellular/immunology , Pituitary Gland, Anterior/immunology , Pituitary Gland, Anterior/surgery , Animals , Dermatitis, Contact/immunology , Dinitrochlorobenzene , Drinking/physiology , Ear, External , Edema/immunology , Erythrocytes/immunology , Extremities , Female , Hemagglutinins/metabolism , Irritants , Organ Size/physiology , Pituitary Gland, Anterior/pathology , Rats , Rats, Wistar , Sheep , Weight Gain/physiologyABSTRACT
We studied the effects of ANG II on extracellular signal-regulated kinase (ERK)1/2 phosphorylation in rat pituitary cells. ANG II increased ERK phosphorylation in a time- and concentration-dependent way. Maximum effect was obtained at 5 min at a concentration of 10-100 nM. The effect of 100 nM ANG II was blocked by the AT1 antagonist DUP-753, by the phospholipase C (PLC) inhibitor U-73122, and by the MAPK kinase (MEK) antagonist PD-98059. The ANG II-induced increase in phosphorylated (p)ERK was insensitive to pertussis toxin blockade and PKC depletion or inhibition. The effect was also abrogated by chelating intracellular calcium with BAPTA-AM or TMB-8 by depleting intracellular calcium stores with a 30-min pretreatment with EGTA and by pretreatment with herbimycin A and PP1, two c-Src tyrosine kinase inhibitors. It was attenuated by AG-1478, an inhibitor of epidermal growth factor receptor (EGFR) activation. Therefore, in the rat pituitary, the increase of pERK is a Gq- and PLC-dependent process, which involves an increase in intracellular calcium and activation of a c-Src tyrosine kinase, transactivation of the EGFR, and the activation of MEK. Finally, the response of ERK activation by ANG II is altered in hyperplastic pituitary cells, in which calcium mobilization evoked by ANG II is also modified.
Subject(s)
Angiotensin II/pharmacology , Mitogen-Activated Protein Kinases/metabolism , Pituitary Gland, Anterior/enzymology , Vasoconstrictor Agents/pharmacology , Animals , Calcium/metabolism , Cells, Cultured , ErbB Receptors/metabolism , Estrogens/metabolism , Female , Hyperplasia , Phosphorylation/drug effects , Pituitary Gland, Anterior/pathology , Protein Kinase C/metabolism , Rats , Rats, Sprague-Dawley , Receptor, Angiotensin, Type 1 , Receptors, Angiotensin/metabolism , Type C Phospholipases/metabolism , src-Family Kinases/metabolismABSTRACT
OBJECTIVE: Somatotrophs represent the majority of cells in the anterior pituitary, and their numeric reduction can cause anterior pituitary hypoplasia (APH). Small numbers of patients with familial isolated GH deficiency (IGHD) due to bi-allelic mutations in the GHRH receptor (GHRHR) gene (GHRHR) have been reported to have APH. We tested if APH was present in a large cohort of patients homozygous and heterozygous for a GHRHR mutation. DESIGN: We studied pituitary morphology in adult and pediatric age subjects (8 years of age and older) belonging to a large extended Brazilian kindred with a high prevalence of IGHD due to a null GHRHR mutation. METHODS: We performed brain magnetic resonance imaging (MRI) in 38 subjects, divided into four groups: group I: normal adults (five males, four females, age 38+/-11.7 years); group II: heterozygous adults (six males, seven females, age 42.23+/-8.8 years); group III: homozygous GH-naive affected adults (three males, five females, age 41.4+/-15.0 years); group IV: homozygous affected children (three males, five females, age 11.9+/-2.5 years). Results are expressed as means+/-s.d. RESULTS: Pituitary height (mm) was not different between groups II and I (4.61+/-1.55 and 4.41+/-0.62 respectively), but it was significantly reduced in groups III (2.67+/-0.87, P<0.001) and IV (2.87+/-0.79, P<0.001) compared with group I. Pituitary volume (mm(3)) was normal in group II (417.12+/-140.86), but it was significantly reduced in groups III and IV (124.06+/-64.27 and 155.68+/-39.79 respectively vs 414.56+/-71.57; both P<0.001). The volume ratio (calculated by multiplying the pituitary volume by 1000 and dividing it by cranial volume) was significantly lower in the affected subjects (groups III and IV) (0.06+/-0.02) than in unaffected (groups I and II) (0.15+/-0.04; P<0.0001), demonstrating that APH is not due to reduction of cranial volume. CONCLUSIONS: APH is present from childhood in patients homozygous for an inactivating GHRHR mutation, but it does not occur in heterozygous subjects. In our cohort, the presence of normal anterior pituitary size by MRI rules out homozygosity for a GHRHR mutation in subjects who are 8 years of age or older.
Subject(s)
Heterozygote , Homozygote , Magnetic Resonance Imaging , Mutation , Pituitary Gland/pathology , Receptors, Neuropeptide/genetics , Receptors, Pituitary Hormone-Regulating Hormone/genetics , Adolescent , Adult , Child , Female , Humans , Insulin-Like Growth Factor I/analysis , Male , Middle Aged , Pituitary Gland, Anterior/pathology , Receptors, Neuropeptide/deficiency , Receptors, Pituitary Hormone-Regulating Hormone/deficiencyABSTRACT
The effect of chronic dexamethasone (DEX) treatment (4-5 days) on Na(+) channel expression was examined in a clonal strain of rat pituitary cells secreting growth hormone (GH) and prolactin (GH3 cells). Using whole-cell patch clamp recording, we found that DEX (1 microM) induces an 80% decrease in Na(+) current density. No concomitant changes in current kinetics or voltage dependence of Na(+) channel function were detected. Instead, the decrease in current density was accompanied by a similar reduction in maximal Na(+) conductance, suggesting the loss of Na(+) channels from the plasma membrane. Accordingly, saxitoxin binding assays carried out on intact cells showed that the average number of Na(+) channels per cell is markedly decreased by DEX. Thus, this glucocorticoid inhibits the cell surface expression of Na(+) channels when chronically applied to GH3 cells.
Subject(s)
Dexamethasone/pharmacology , Down-Regulation , Glucocorticoids/pharmacology , Pituitary Gland, Anterior/metabolism , Sodium Channels/drug effects , Animals , Growth Hormone/metabolism , Ion Channel Gating , Patch-Clamp Techniques , Pituitary Gland, Anterior/pathology , Prolactin/metabolism , Rats , Sodium Channels/physiology , Tumor Cells, CulturedABSTRACT
OBJECTIVE: Herpes simplex virus type 1 (HSV-1)-derived vectors are known to be effective tools to deliver transgenes into normal and neoplastic anterior pituitary (AP) cells in vitro. Our objective was to assess the in vitro and in vivo effects of tsK/beta-gal, a temperature-sensitive HSV-1-derived vector harbouring the E. coli beta-galactosidase gene, on AP hormone secretion as well as on transgene expression in rat AP tumours (hyperplastic prolactinomas). DESIGN: The impact of vector infection on prolactin (PRL) and GH release was determined in vitro in normal and hyperplastic (lactotrophic) dispersed AP cells exposed for 24 h to tsK/beta-gal as well as in vivo in ectopic AP grafts. In some oestrogen-induced prolactinoma-carrying rats, vector suspension was stereotaxically injected into the glands to assess transgene expression in vivo. METHODS: GH and PRL release was measured by specific RIAs. In vivo transgene expression was assessed by immunohistochemistry for beta-galactosidase and enzymohistochemistry (5-bromo-4-chloro-3-indolyl-beta-d-galactopyranoside). Ectopic pituitary grafts and stereotaxic surgery were performed following standard procedures. RESULTS: At a multiplicity of infection of 0.5, the vector induced a 30 and 22% fall in PRL and GH release respectively in normal AP cells, whereas the corresponding hormone release inhibition for hyperplastic AP cells was 41 and 33% for PRL and GH respectively. In ectopic pituitary grafts, the effect of vector infection on hormone secretion was assessed by measuring serum PRL levels in the host rats every 5 days for 4 weeks post-grafting. In the pituitary-grafted rats that received the viral vector, serum PRL failed to increase to the levels achieved in control-grafted animals. Finally, pituitary tumours stereotaxically injected with tsK/beta-gal showed widespread expression of the beta-galactosidase transgene around the injection areas. CONCLUSIONS: The results reported here have implications for basic studies using gene transfer to pituitary gland as well as potential gene therapy approaches to pituitary diseases.
Subject(s)
Gene Transfer Techniques , Pituitary Gland, Anterior/physiology , Pituitary Hormones/metabolism , Animals , Cells, Cultured , Female , Gene Expression , Genetic Vectors , Growth Hormone/metabolism , Herpesvirus 1, Human/genetics , Hyperplasia , Mutation , Pituitary Gland, Anterior/cytology , Pituitary Gland, Anterior/metabolism , Pituitary Gland, Anterior/pathology , Pituitary Neoplasms/genetics , Pituitary Neoplasms/metabolism , Pituitary Neoplasms/pathology , Prolactin/blood , Prolactin/metabolism , Prolactinoma/genetics , Prolactinoma/metabolism , Prolactinoma/pathology , Rats , Rats, Sprague-Dawley , Reference Values , Transgenes/physiologyABSTRACT
Considerable attention has currently been focused on bisphenol A (BPA), an environmental endocrine disrupting chemical that has oestrogenic activity. In vitro and in vivo short-term assays have shown that BPA is weakly estrogenic. In addition, the issue of species- and strain-differences in susceptibility to BPA was raised. The treatment of ovariectomized (OVX) Wistar rats with BPA at doses of 11-250 mg/kg per day, s.c., for 7 days, resulted in significant dose-dependent regrowth of uterus in uterotrophic assay. Additionally, the stimulation of anterior pituitary gland growth and induction of hyperprolactinaemia, as determined by wet organ weight and radioimmunoassay (RIA), respectively, were also dose-dependent (at 128 and 250 mg/kg per day, P < 0.05). Prolactin immunostaining of anterior pituitary glands revealed that BPA at a dose of 250 mg/kg per day increased the number of prolactin-immunopositive cells by 63% compared to OVX rats. These results demonstrate that the reproductive tract and neuroendocrine axis of Wistar rats are able to respond to BPA. Furthermore, the pituitary gland hypertrophy and hyperprolactinaemia can be mediated, at least partly, by increase in number of prolactin-immunoreactive cells. The long-term consequences of this proliferation are yet unknown but neoplasm formation is an obvious possibility.
Subject(s)
Estrogens, Non-Steroidal/toxicity , Phenols/toxicity , Pituitary Gland/drug effects , Prolactin/blood , Uterus/drug effects , Animals , Benzhydryl Compounds , Body Weight/drug effects , Eating/drug effects , Energy Metabolism/drug effects , Female , Immunoenzyme Techniques , Injections, Subcutaneous , Organ Size/drug effects , Ovariectomy , Pituitary Gland/metabolism , Pituitary Gland/pathology , Pituitary Gland, Anterior/chemistry , Pituitary Gland, Anterior/pathology , Rats , Rats, Wistar , Uterus/pathologyABSTRACT
We describe two female infants with congenital nasal pyriform aperture stenosis and severe pituitary insufficiency. The anterior pituitary gland was undetectable with magnetic resonance imaging. Consanguinity of parents in both cases suggests autosomal recessive inheritance of this disorder. An early fetal developmental defect may explain this syndrome, which affects midline craniofacial structures. In patients with congenital pyriform aperture stenosis, magnetic resonance imaging of the brain and endocrine investigations should be performed for rapid diagnosis and treatment of the latter to avoid major neurologic complications.